biostudies-literatureWen RMNIH, DoDNCRR NIH HHSNCI NIH HHSNIGMS NIH HHSe180282https://www.ebi.ac.uk/biostudies/studies/S-EPMC11645153biostudies-literatureUnknown134(24)Prostate cancer is the second leading cause of male cancer death in the U.S. Current immune checkpoint inhibitor-based immunotherapies have improved survival for many malignancies; however, they have failed to prolong survival for prostate cancer. Siglecs (sialic acid-binding immunoglobulin-like lectins) are expressed on immune cells and regulate their function. Siglec-7 and Siglec-9 contribute to immune evasion in cancer by interacting with sialic acid-containing glycoprotein ligands on cancer cells. However, the role of Siglec-7/9 receptors and their ligands in prostate cancer remains poorly understood. Here, we find that Siglec-7 and Siglec-9 are associated with poor prognosis in patients with prostate cancer and are highly expressed in myeloid cells, including macrophages, in prostate The Journal of clinical investigationSialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer.PMC11645153F32 CA250324S10 RR025518W81XWH2110195,1F32CA250324-01,PF-20-143-01-LIB,R01CA227942,NIH K99 GM147304,U01CA226051,S10RR025518-01,S10RR027431-01P30 CA014051U01 CA226051K99 GM147304R01 CA227942S10 RR027431Brooks JDGarcia Marques FJPitteri SJFan ZEngleman EGTotten SMBertozzi CRWen RMFong LLyu AStark JCRiley NMZhang XBermudez AMarti GEWNolley RZhao HfalseSialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer.Prostate cancer is the second leading cause of male cancer death in the U.S. Current immune checkpoint inhibitor-based immunotherapies have improved survival for many malignancies; however, they have failed to prolong survival for prostate cancer. Siglecs (sialic acid-binding immunoglobulin-like lectins) are expressed on immune cells and regulate their function. Siglec-7 and Siglec-9 contribute to immune evasion in cancer by interacting with sialic acid-containing glycoprotein ligands on cancer cells. However, the role of Siglec-7/9 receptors and their ligands in prostate cancer remains poorly understood. Here, we find that Siglec-7 and Siglec-9 are associated with poor prognosis in patients with prostate cancer and are highly expressed in myeloid cells, including macrophages, in prostate 2024-01-01T00:00:00Z2024 Oct2026-06-02T10:45:57.252Z2025-04-04T01:54:59.075ZS-EPMC116451533943670310.1172/JCI180282